InnovationRx: Positive Clinical Trial Results For Generative AI-Designed Drug
Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.
Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis
Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...
Aileron Therapeutics Reports Positive Phase 1b Data Of LTI-03 In Idiopathic Pulmonary Fibrosis
(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).
GEN1d
Insilico Plans Pivotal Trial for AI-Based IPF Candidate
The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...
The American Journal of Managed Care1d
Novel, AI-Procured ISM001-055 Demonstrates Great Promise for Treatment of IPF
The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options ...
BioSpace1d
Insilico Aces Second Mid-Stage IPF Trial in a Row
In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and ...
Daily2d
Constipation linked to survival of patients with idiopathic interstitial pneumonias, finds study
Idiopathic pulmonary fibrosis (IPF), the most common phenotype of IIPs ... To do this, they employed a marginal structural ...
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic ...